
#### Revisions are highlighted with a image


Alberta Health Services Monoclonal antibody, Antiviral agent			OTHER NAMES:		sotrovimab		
ROUTE of ADMINISTRATION	INTRAVENOUS		S			ANEOUS	IM
	Direct IV	Intermittent	Continuous	Injection		Infusion	
	NO	YES <sup>1</sup>	NO	NO		NO	NO
<b>REQUIRED EDUCATION, EQUIPMENT OR MONITORING</b> 1. Administer with a 0.2 or 0.22 micron filter.							
INDICATIONS							

- Mild to moderate Coronavirus disease 2019 (COVID-19) at high risk of progressing to hospitalization or death.
- Refer to <u>AHS Provincial Drug Formulary</u> for restrictions and more information.


# CONTRAINDICATIONS / CAUTIONS CONTRAINDICATIONS

• Hypersensitivity to sotrovimab or excipients.





to 5 times to mix. Do not invert the infusion bag.



# CLINICAL IMPLICATIONS

- Assess for hypersensitivity/ infusion reactions during infusion and monitor for at least 1 hour after infusion is complete.
- If an infusion-related reaction occurs, slow or stop the infusion. Administer supportive care as required.

# **PRODUCT DESCRIPTION / RECONSTITUTION / STABILITY**

### PRODUCT DESCRIPTION

- Available as 62.5 mg/mL injection.
- Refrigerate unopened products and protect from light. Do not shake.
- Sotrovimab may contain polysorbate 80 (Tween).

IV SOLUTION STABILITY (Please note that stability information does not apply to parenteral products mixed by Pharmacy).

• NS: Stable for 4 hours at room temperature or 24 hours refrigerated.

## COMPATIBILITY

- The parenteral monographs are not meant to be a comprehensive source of compatibility information. For the most current and complete listing of compatibility data, please consult Micromedex or Lexicomp.
- Drug IV compatibility is dependent on a number of factors including tested concentrations, diluents and storage conditions. See monograph template for more detailed information.
- Compatibility of MORE THAN TWO drugs in the same line or container may NOT be inferred from any information presented in the following intravenous compatibility charts.

No compatibility studies have been done. Do NOT mix with other drugs in the same IV line. FOR ALBERTA HEALTH SERVICES USE Unauthorized distribution, copying or disclosure

ONLY.

PROHIBITED. Last Revised: Nov 3, 2021 sotrovimab (Version 1)

Ensure paper copies are reviewed for new versions at least every 30 days.